Recombinant human gamma-interferon in primary hepatocellular carcinoma

Alastair Forbes; Philip J. Johnson; Roger Williams

doi:10.1177/014107688507801007

Recombinant human gamma-interferon in primary hepatocellular carcinoma

Alastair Forbes, Philip J. Johnson, Roger Williams

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.

Original language	English
Pages (from-to)	826-829
Number of pages	4
Journal	Journal of the Royal Society of Medicine
Volume	78
Issue number	10
DOIs	https://doi.org/10.1177/014107688507801007
Publication status	Published - Oct 1985

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adult
Carcinoma, Hepatocellular
Drug Evaluation
Female
Humans
Interferon-gamma
Liver Neoplasms
Male
Middle Aged
Time Factors
alpha-Fetoproteins

Access to Document

10.1177/014107688507801007

Cite this

@article{998a89b34ee44f0e9831c34b5485db63,

title = "Recombinant human gamma-interferon in primary hepatocellular carcinoma",

abstract = "A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.",

keywords = "Adult, Carcinoma, Hepatocellular, Drug Evaluation, Female, Humans, Interferon-gamma, Liver Neoplasms, Male, Middle Aged, Time Factors, alpha-Fetoproteins",

author = "Alastair Forbes and Johnson, {Philip J.} and Roger Williams",

year = "1985",

month = oct,

doi = "10.1177/014107688507801007",

language = "English",

volume = "78",

pages = "826--829",

journal = "Journal of the Royal Society of Medicine",

issn = "0141-0768",

publisher = "Sage Publications",

number = "10",

}

TY - JOUR

T1 - Recombinant human gamma-interferon in primary hepatocellular carcinoma

AU - Forbes, Alastair

AU - Johnson, Philip J.

AU - Williams, Roger

PY - 1985/10

Y1 - 1985/10

N2 - A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.

AB - A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.

KW - Adult

KW - Carcinoma, Hepatocellular

KW - Drug Evaluation

KW - Female

KW - Humans

KW - Interferon-gamma

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Time Factors

KW - alpha-Fetoproteins

U2 - 10.1177/014107688507801007

DO - 10.1177/014107688507801007

M3 - Article

C2 - 2413205

SN - 0141-0768

VL - 78

SP - 826

EP - 829

JO - Journal of the Royal Society of Medicine

JF - Journal of the Royal Society of Medicine

IS - 10

ER -